The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

The stability of Pt-based catalysts is critical to the reliability of proton exchange membrane fuel cells. Here, the authors use stroboscopic operando high energy X-ray scattering to reveal Pt ...

Bacteria in the gut have been implicated in autoimmune diseases, like lupus, that don't primarily affect the gastrointestinal ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

Mass General Brigham researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

The odds of developing systemic lupus erythematosus or systemic sclerosis appear to significantly increase with the use of ...

The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene ...

Researchers have discovered a new type of tissue, a soft and flexible ‘fatty cartilage’ that could revolutionize the ...

When Aleta was first diagnosed with lupus, she wasn’t ready to share her diagnosis with anyone beyond her closest family and ...